Indian stocks: Visit www.stage2stocks.com →

BioVie Inc.

Stage 3 · Topping · week 5

As of Oct 22, 2026, BioVie is in Stage 3, the topping phase, now in week 5 (since Sep 24, 2026). It closed at $1.28, 43.9% below its 52-week high and below its 200-day average, which is falling.

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. More about the company

$1.28
+2.15% today
$11.1M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is BIVI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 49w
S4 20w
S4 16w
S4 18w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 12w → S1 4w → S4 49w → S1 9w → S4 20w → S1 5w → S4 16w → S1 1w → S4 18w → S1 11w → S2 9w → S3 2w → S2 4w → S3 4w current
Total tracked: 165 weeks across 14 stage runs.

BIVI among Biotechnology289th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…289BIVIStage 3 · wk 532−21.5%
vs 52W High
-43.9%
$0.96 lo$2.28 hi
43.9% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 5
1w13w26w
Week 5, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-15.5%
200 DMA: $1.51 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.02x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-21.5%
3M
-6.6%
6M
-10.5%
YTD
-3.8%
1Y
-33.0%
Scan Membership
Breakout Watch
Latest: 2023-03-21
2 appearances in last 60 days. First seen: 2022-11-03.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 5 · Vol 0.02x
2026-10-21S3
Wk 4 · Vol 0.03x
2026-10-20S3
Wk 4 · Vol 0.05x
2026-10-19S3
Wk 4 · Vol 0.03x
2026-10-16S3
Wk 4 · Vol 0.05x
2026-10-15S3
Wk 4 · Vol 0.03x
2026-10-14S3
Wk 3 · Vol 0.06x
2026-10-13S3
Wk 3 · Vol 0.03x
2026-10-12S3
Wk 3 · Vol 0.01x
2026-10-09S3
Wk 3 · Vol 0.04x
2026-10-08S3
Wk 3 · Vol 0.06x
2026-10-07S3
Wk 2 · Vol 0.02x
Moving averages & range
50 DMA
$1.64
200 DMA
$1.51
52W High
$2.28
52W Low
$0.96
5D Low
$1.20
Resistance levels (recent highs)
20d High
$1.61
60d High
$2.28
120d High
$2.28
250d High
$2.28
Next resistance
+25.4%
to 20d High
ROE
-150.8%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.9

BioVie: quick answers

What stage is BioVie in?

As of Oct 22, 2026, BioVie (BIVI) is in Stage 3, the topping phase. It entered Stage 3 on Sep 24, 2026 and is in week 5. What the four stages mean

Is BioVie in an uptrend?

Its uptrend has stalled. BioVie is in Stage 3, the topping phase that follows an advance. It trades 15.5% below its 200-day average, which is falling.

How far is BioVie from its 52-week high?

BioVie closed at $1.28 on Oct 22, 2026, 43.9% below its 52-week high of $2.28. Its 52-week low is $0.96.

How has BioVie performed over the past year?

As of Oct 22, 2026, BioVie is down 33.0% over the past year and down 3.8% so far in 2026.

Which sector and industry is BioVie in?

BioVie is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.